A review of becaplermin gel in the treatment of diabetic neuropathic foot ulcers

Robert C. Fang, Robert D Galiano

Research output: Contribution to journalReview articlepeer-review

69 Scopus citations


Diabetic neuropathic foot ulcers represent a serious health care burden to patients and to society. While the management of chronic diabetic foot ulcers has improved in recent years, it remains a frustrating problem for a variety of clinicians. This review examines the scientifi c underpinnings supporting the use of becaplermin (Regranex®; Ortho-McNeil Pharmaceutical, Raritan, NJ), or recombinant human platelet-derived growth factor (rhPDGF-BB), in diabetic forefoot wounds. An emphasis is placed upon proper medical and surgical care of diabetic foot wounds, as multiple studies have demonstrated that the success of this growth factor in accelerating healing is ultimately dependent on proper ulcer care. A focus on the costeffectiveness of this form of therapy in the treatment of diabetic foot ulcers is also outlined.

Original languageEnglish (US)
Pages (from-to)1-12
Number of pages12
JournalBiologics: Targets and Therapy
Issue number1
StatePublished - Dec 1 2008


  • Becaplermin
  • Diabetes
  • Foot ulcer
  • Growth factor

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Oncology
  • Gastroenterology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'A review of becaplermin gel in the treatment of diabetic neuropathic foot ulcers'. Together they form a unique fingerprint.

Cite this